
Sign up to save your podcasts
Or


Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.
By Norstella4.1
2828 ratings
Interventional cardiologist and Soley Therapeutics CEO Yerem Yeghiazarians joins In Vivo’s David Wild to unpack how decoding cell stress with live‑cell imaging and AI is driving a new oncology pipeline, and what it takes to build a platform‑plus‑pipeline biotech while still practicing medicine.

1,290 Listeners

1,713 Listeners

4,420 Listeners

406 Listeners

154 Listeners

1,036 Listeners

837 Listeners

337 Listeners

1,320 Listeners

6,097 Listeners

1,281 Listeners

34 Listeners

678 Listeners

21 Listeners

170 Listeners